Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2008 2
2010 5
2011 7
2012 3
2013 2
2014 1
2015 4
2016 3
2017 3
2018 2
2019 2
2020 1
2021 4
2022 5
2023 14
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Results by year

Filters applied: . Clear all
Page 1
Translation efficiency driven by CNOT3 subunit of the CCR4-NOT complex promotes leukemogenesis.
Ghashghaei M, Liu Y, Ettles J, Bombaci G, Ramkumar N, Liu Z, Escano L, Miko SS, Kim Y, Waldron JA, Do K, MacPherson K, Yuen KA, Taibi T, Yue M, Arsalan A, Jin Z, Edin G, Karsan A, Morin GB, Kuchenbauer F, Perna F, Bushell M, Vu LP. Ghashghaei M, et al. Among authors: perna f. Nat Commun. 2024 Mar 15;15(1):2340. doi: 10.1038/s41467-024-46665-2. Nat Commun. 2024. PMID: 38491013 Free PMC article.
Alternative immune effector cells picking up speed.
Weber E, Bleakley M, Cronk JC, Shah NN, Perna F. Weber E, et al. Among authors: perna f. Mol Ther. 2024 Mar 6;32(3):563-564. doi: 10.1016/j.ymthe.2024.01.030. Epub 2024 Feb 9. Mol Ther. 2024. PMID: 38340733 No abstract available.
Shifting gears with CAR T cells for autoimmune diseases.
Kale B, Khosravi-Maharlooei M, Perna F. Kale B, et al. Among authors: perna f. Mol Ther. 2024 Feb 7;32(2):261-263. doi: 10.1016/j.ymthe.2024.01.014. Epub 2024 Jan 20. Mol Ther. 2024. PMID: 38244538 No abstract available.
The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability.
Ravn-Boess N, Roy N, Hattori T, Bready D, Donaldson H, Lawson C, Lapierre C, Korman A, Rodrick T, Liu E, Frenster JD, Stephan G, Wilcox J, Corrado AD, Cai J, Ronnen R, Wang S, Haddock S, Sabio Ortiz J, Mishkit O, Khodadadi-Jamayran A, Tsirigos A, Fenyö D, Zagzag D, Drube J, Hoffmann C, Perna F, Jones DR, Possemato R, Koide A, Koide S, Park CY, Placantonakis DG. Ravn-Boess N, et al. Among authors: perna f. Cell Rep. 2023 Nov 28;42(11):113374. doi: 10.1016/j.celrep.2023.113374. Epub 2023 Nov 8. Cell Rep. 2023. PMID: 37938973 Free PMC article.
A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma.
Di Meo F, Iyer A, Akama K, Cheng R, Yu C, Cesarano A, Kurihara N, Tenshin H, Aljoufi A, Marino S, Soni RK, Roda J, Sissons J, Vu LP, Guzman M, Huang K, Laskowski T, Broxmeyer HE, Roodman DG, Perna F. Di Meo F, et al. Among authors: perna f. Cell Rep Med. 2023 Jul 18;4(7):101110. doi: 10.1016/j.xcrm.2023.101110. Cell Rep Med. 2023. PMID: 37467717 Free PMC article.
61 results